PL1616011T3 - Chimeryczne polipeptydy i ich zastosowanie - Google Patents

Chimeryczne polipeptydy i ich zastosowanie

Info

Publication number
PL1616011T3
PL1616011T3 PL04727873T PL04727873T PL1616011T3 PL 1616011 T3 PL1616011 T3 PL 1616011T3 PL 04727873 T PL04727873 T PL 04727873T PL 04727873 T PL04727873 T PL 04727873T PL 1616011 T3 PL1616011 T3 PL 1616011T3
Authority
PL
Poland
Prior art keywords
dna
activity
activities
chimeric molecules
region
Prior art date
Application number
PL04727873T
Other languages
English (en)
Polish (pl)
Inventor
Christian Kühne
Andras Simoncsits
Original Assignee
Adriacell S P A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adriacell S P A filed Critical Adriacell S P A
Publication of PL1616011T3 publication Critical patent/PL1616011T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K19/00Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/16Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/10Anthelmintics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/06Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62DNA sequences coding for fusion proteins
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/16Hydrolases (3) acting on ester bonds (3.1)
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/33Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y301/00Hydrolases acting on ester bonds (3.1)
    • C12Y301/21Endodeoxyribonucleases producing 5'-phosphomonoesters (3.1.21)
    • C12Y301/21004Type II site-specific deoxyribonuclease (3.1.21.4)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • General Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Virology (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
PL04727873T 2003-04-18 2004-04-16 Chimeryczne polipeptydy i ich zastosowanie PL1616011T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IT000821A ITMI20030821A1 (it) 2003-04-18 2003-04-18 Polipeptidi chimerici e loro uso.
EP04727873A EP1616011B1 (en) 2003-04-18 2004-04-16 Chimeric polypeptides and their use
PCT/EP2004/004062 WO2004092194A2 (en) 2003-04-18 2004-04-16 Chimeric polypeptides and their use

Publications (1)

Publication Number Publication Date
PL1616011T3 true PL1616011T3 (pl) 2008-05-30

Family

ID=33187374

Family Applications (1)

Application Number Title Priority Date Filing Date
PL04727873T PL1616011T3 (pl) 2003-04-18 2004-04-16 Chimeryczne polipeptydy i ich zastosowanie

Country Status (16)

Country Link
US (3) US20060292629A1 (https=)
EP (1) EP1616011B1 (https=)
JP (2) JP4794432B2 (https=)
KR (2) KR101360781B1 (https=)
CN (1) CN100584950C (https=)
AT (1) ATE374826T1 (https=)
AU (1) AU2004230254B2 (https=)
CA (1) CA2522525A1 (https=)
CY (1) CY1107115T1 (https=)
DE (1) DE602004009301T2 (https=)
DK (1) DK1616011T3 (https=)
ES (1) ES2293247T3 (https=)
IT (1) ITMI20030821A1 (https=)
PL (1) PL1616011T3 (https=)
PT (1) PT1616011E (https=)
WO (1) WO2004092194A2 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20030821A1 (it) * 2003-04-18 2004-10-19 Internat Ct For Genetic En Gineering And Polipeptidi chimerici e loro uso.
NL1027479C2 (nl) * 2004-10-21 2006-05-01 Synvolux Ip B V Bescherming van biologisch actieve moleculen met behulp van amphifielen.
ATE464395T1 (de) * 2005-02-18 2010-04-15 Astrazeneca Ab Verfahren zur bestimmung der reaktionsfähigkeit gegenüber chk1-inhibitoren
GB0609119D0 (en) * 2006-05-09 2006-06-21 Univ Birmingham Histones
WO2008141096A2 (en) * 2007-05-11 2008-11-20 The Regents Of The University Of California Nucleic acids for inducing expression of transcripts and proteins and methods for making and using them
CA2939694A1 (en) 2014-02-17 2015-08-20 Universite Claude Bernard Lyon 1 Predictive method of characterizing the radiosensitivity and tissular reaction of a patient to therapeutic ionizing radiation
CN104193826B (zh) * 2014-09-17 2018-02-23 山东大学齐鲁医院 一种融合多肽及其在制备抗肿瘤药物中的应用
CA3019629A1 (en) * 2016-04-12 2017-10-19 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Methylmalonyl coenzyme a mutase (mcm) fusion constructs for the treatment of disorders associated with mcm deficiency
JP6925003B2 (ja) * 2016-05-10 2021-08-25 公立大学法人横浜市立大学 非相同末端連結欠損細胞及びその利用
WO2017205852A2 (en) * 2016-05-27 2017-11-30 Synthex, Inc. Protein interfaces
WO2017211941A1 (en) * 2016-06-09 2017-12-14 Alma Mater Studiorum Universita Di Bologna Herpesvirus with modified glycoprotein b
CA3067382A1 (en) 2017-06-15 2018-12-20 The Regents Of The University Of California Targeted non-viral dna insertions
KR102503130B1 (ko) 2017-10-27 2023-02-24 더 리전트 오브 더 유니버시티 오브 캘리포니아 내인성 t 세포 수용체의 표적화된 대체
GB2584210B (en) 2017-11-22 2022-03-16 Synthex Inc Peptides for inhibiting RAD51
AU2022366987A1 (en) 2021-10-14 2024-05-16 Arsenal Biosciences, Inc. Immune cells having co-expressed shrnas and logic gate systems
WO2023111213A1 (en) 2021-12-16 2023-06-22 Rdp Pharma Ag Cell penetrating polypeptides (cpps) and their use in human therapy
CN116023512A (zh) * 2023-02-16 2023-04-28 浙江大学 一条靶向dna损伤修复蛋白的多肽及其用途
EP4480497A1 (en) 2023-06-21 2024-12-25 RDP Pharma AG Bio-conjugates for oncology

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5670617A (en) * 1989-12-21 1997-09-23 Biogen Inc Nucleic acid conjugates of tat-derived transport polypeptides
WO2000046386A2 (en) * 1999-02-03 2000-08-10 The Children's Medical Center Corporation Gene repair involving the induction of double-stranded dna cleavage at a chromosomal target site
WO2000058488A2 (en) * 1999-03-31 2000-10-05 Invitrogen Corporation Delivery of functional protein sequences by translocating polypeptides
AU4430701A (en) * 2000-04-03 2001-10-15 Antisoma Research Limited Compounds for targeting
GB0112818D0 (en) * 2001-05-25 2001-07-18 Lorantis Ltd Conjugate
EP1342781A1 (en) * 2002-03-09 2003-09-10 ARTEMIS Pharmaceuticals GmbH Recombinase fusion protein with enhanced cellular uptake
EP2806025B1 (en) * 2002-09-05 2019-04-03 California Institute of Technology Use of zinc finger nucleases to stimulate gene targeting
ITMI20030821A1 (it) * 2003-04-18 2004-10-19 Internat Ct For Genetic En Gineering And Polipeptidi chimerici e loro uso.

Also Published As

Publication number Publication date
CY1107115T1 (el) 2012-01-25
US20150018409A1 (en) 2015-01-15
JP2006523448A (ja) 2006-10-19
EP1616011B1 (en) 2007-10-03
PT1616011E (pt) 2008-01-07
US20060292629A1 (en) 2006-12-28
KR20110074948A (ko) 2011-07-04
WO2004092194A3 (en) 2005-03-17
EP1616011A2 (en) 2006-01-18
CN1768142A (zh) 2006-05-03
JP4794432B2 (ja) 2011-10-19
DE602004009301D1 (de) 2007-11-15
KR101360781B1 (ko) 2014-04-24
ES2293247T3 (es) 2008-03-16
KR20060003029A (ko) 2006-01-09
ATE374826T1 (de) 2007-10-15
KR101247704B1 (ko) 2013-03-26
US20110033384A1 (en) 2011-02-10
DK1616011T3 (da) 2008-02-04
ITMI20030821A1 (it) 2004-10-19
AU2004230254B2 (en) 2008-10-02
DE602004009301T2 (de) 2008-07-17
AU2004230254A1 (en) 2004-10-28
JP2011182792A (ja) 2011-09-22
CA2522525A1 (en) 2004-10-28
CN100584950C (zh) 2010-01-27
WO2004092194A2 (en) 2004-10-28

Similar Documents

Publication Publication Date Title
PL1616011T3 (pl) Chimeryczne polipeptydy i ich zastosowanie
Dunnill Triplet Nucleotide–Amino-acid Pairing; a Stereo-chemical Basis for the Division between Protein and Non-protein Amino-acids
ATE380828T1 (de) Modifizierte peptide als therapeutische mittel
EA200700408A1 (ru) Транспортный белок для доставки химических соединений в нервные клетки
MX2008001509A (es) Peptidos protectores de tejido y sus usos.
WO2005046709A3 (en) Tgf - beta binding and supported peptides
CA2345903A1 (en) Molecular pathogenicide mediated plant disease resistance
WO2003076592A3 (en) Novel method for delivery and intracellular synthesis of sirna molecules
WO2009001260A3 (en) Cosmetic use of apolipoprotein d type proteins
BRPI0412607A (pt) método para aprimorar a eficácia de proteìnas modificantes de reação biológica e muteìnas resultantes
WO2002000721A3 (en) Cytokine receptor zcytor17
ATE306498T1 (de) Von zellen präsentierte peptide
Miura et al. Cyclic β2, 3-amino acids improve the serum stability of macrocyclic peptide inhibitors targeting the SARS-CoV-2 main protease
Katoh et al. Ribosomal incorporation of negatively charged d-α-and N-methyl-l-α-amino acids enhanced by EF-Sep
WO2007015771A3 (en) Composition and method for introduction of rna interference sequences into targeted cells and tissues
WO2005056595A3 (en) T cell receptor specific for wilms tumor antigen
WO2004045544A8 (en) Autocrine growth factor receptor antibodies and methods
WO2006069203A3 (en) Methods for proteomic profiling using non-natural amino acids
Wei et al. Immobilized acyl-transfer molecular reactors enable the solid-phase synthesis of sterically hindered peptides
Okuma et al. A Macrocyclic Peptide Library with a Structurally Constrained Cyclopropane‐containing Building Block Leads to Thiol‐independent Inhibitors of Phosphoglycerate Mutase
BR0317161A (pt) Moléculas de ligação nogo a e uso farmacêutico das mesmas
GB0424560D0 (en) Heart valve tissue engineering
WO2002044409A3 (en) Substrate linked directed evolution (slide)
WO2007060213A3 (en) Erythropoietin polypeptides and uses thereof
ATE520025T1 (de) Test für morbus-parkinson-therapeutika